Answers are grounded in this paper and cite their sources.
Findings identify HSDL2’s role in modulating synaptic excitability and inhibiting NMDAR activity in epilepsy, suggesting new therapeutic strategies.
Our findings identify HSDL2 as a novel endogenous antiseizure protein that confers protection in epilepsy by modulating synaptic excitability. Specifically, HSDL2 regulates the PSD95-NMDAR complex through post-translational modification of PSD95, thereby inhibiting excessive NMDAR activity. Its therapeutic modulation may offer a strategy for drug development in TLE.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: